Patents by Inventor Cameron M. Douglas

Cameron M. Douglas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assays for resistance to echinocandin-class drugs
    Patent number: 10934577
    Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: March 2, 2021
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, MERCK & CO., INC.
    Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
  • ASSAYS FOR RESISTANCE TO ECHINOCANDIN-CLASS DRUGS
    Publication number: 20170356034
    Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.
    Type: Application
    Filed: May 22, 2017
    Publication date: December 14, 2017
    Applicants: Rutgers, The State University of New Jersey, Merck & Co., Inc.
    Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
  • Assays for resistance to echinocandin-class drugs
    Patent number: 9657334
    Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: May 23, 2017
    Assignees: Rutgers, The State University of New Jersey, Merck & Co., Inc.
    Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
  • Assays for resistance to echinocandin-class drugs
    Publication number: 20150125856
    Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.
    Type: Application
    Filed: June 16, 2014
    Publication date: May 7, 2015
    Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
  • Assays for resistance to echinocandin-class drugs
    Patent number: 8753819
    Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: June 17, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer Nielsen Kahn, Stephen A. Parent, Rosemarie Kelly
  • Assays for Resistance to Echinocandin-Class Drugs
    Publication number: 20100075302
    Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.
    Type: Application
    Filed: July 26, 2006
    Publication date: March 25, 2010
    Applicants: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, MERCK & CO.
    Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer Nielsen Kahn, Stephen A. Parent, Rosemarie Kelly
  • DNA encoding 1,3 beta-D glucan synthase subunits
    Patent number: 5821353
    Abstract: DNA molecules encoding proteins involved in biosynthesis of 1,3-beta-D glucan are identified, cloned, expressed and used in in vitro assays to screen for antifungal compounds, including compounds that affect cell wall biosynthesis. The invention includes but is not limited to the purified DNA molecules, assays employing the DNA molecules, proteins encoded by the DNA molecules, cells expressing the DNA molecules and altered forms of the molecules.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Cameron M. Douglas, Gary L. Chrebet, Joseph Clemas, Mohammed El-Sherbeini, Forrest Foor, Jennifer Nielsen Kahn, Rosemarie Kelly, Jean A. Marrinan, Nancy R. Morin, Janet C. Onishi, Stephen Authur Parent, Naasa M. Ramadan, Elizabeth A. Register, Gan-Ju Shei